MatthewNeilBramsMD

Psychiatry • Houston, TX

Child & Adolescent Psychiatry

Clinical Assistant Professor, Psychiatry & Behavioral Sciences, Baylor College of Medicine

Join to view full profile

Dr. Brams is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brams' full profile

Already have an account?

Office
550 Westcott St
St 520
Houston, TX 77007
Phone+1 713-864-6696

Fax+1 713-864-6698

Education & Training

Baylor College of MedicineFellowship, Child and Adolescent Psychiatry, 1990 - 1992
Baylor College of MedicineResidency, Psychiatry, 1987 - 1990
McGovern Medical School at UTHealthClass of 1987

Certifications & Licensure

TX State Medical License 1988 - 2025
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD Start of enrollment: 2005 May 01
Completed
Phase 3
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2014 Mar 01
Completed
Phase 3
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients Start of enrollment: 2014 Apr 01
Completed
Phase 3
PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
Completed
Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD Start of enrollment: 2014 May 01
Completed
Phase 3
Dasotraline Pediatric ADHD Study Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
Dasotraline Pediatric Extension Study Start of enrollment: 2015 Jun 30
Completed
Phase 3
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Completed
Phase 3
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting Start of enrollment: 2015 Jul 01
Completed
Phase 3
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Nov 19
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.
Andrew J Cutler, Scott H Kollins, Matthew N Brams, Meg Corliss, Charles Oh
Frontiers in Psychiatry. 2024-01-01
4 citations
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety S...
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams
Journal of Child and Adolescent Psychopharmacology. 2023-03-01
3 citations
Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
Richard Jackson, Matthew N Brams, Noelle E Carlozzi, Leslie Citrome, Nora E Fritz
The Journal of Clinical Psychiatry. 2022-11-28

Press Mentions

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (Dexmethylphenidate) for ADHDApril 4th, 2023
Cingulate Announces Positive Fed/Fast Study Results of CTx-1301 ADHD Lead AssetFebruary 23rd, 2023
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHDFebruary 23rd, 2023
Join now to see all